Vascular Solutions' thrombus extractor:
This article was originally published in Clinica
Vascular Solutions has received US FDA 510(k) clearance to sell a version of its Pronto extraction catheter that is sufficiently large but also short enough to remove thrombus from haemodialysis grafts and fistulas. The Pronto-Short device will be used to treat the relatively large-sized grafts and fistulas, which are prone to clotting, with patients requiring on average one de-clot procedure each year, according to the Minneapolis, Minnesota firm. The original Pronto device is designed to remove thrombi from arteries. The firm estimates the additional US market opportunity addressed by the Pronto-Short to be around $100m annually.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.